This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, S. H. Articles by Yoo, N. J. Search for Related Content PubMed PubMed Citation Articles by Lee, S. H. Articles by Yoo, N. J.

Point Mutations and Deletions of the Bcl10 Gene in Solid Tumors andMalignant Lymphomas¹

Departments of Pathology [S. H. L., M. S. S., H. S. K., W. S. P., S. Y. K., H. K. L., J. Y. P., R. R. O., J. Y. L., N. J. Y.], Internal Medicine [J. Y. H.], Clinical Pathology [C. S. K.], and Cancer Research Institute [S. H. L., J. Y. L., W. S. P., N. J. Y.], College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea; Department of Pathology and Cancer Research Center, Seoul National University College of Medicine, Seoul 110-799, Korea [J. J. J.]; Department of Pathology, Sanggye Paik Hospital, College of Medicine, Inje University, Seoul 139-707, Korea [K. M. P.]

The Bcl10 gene, which encodes a protein with proapoptotic activity, recently has been identified on chromosome 1p22. In this study, we analyzed somatic mutations and deletions of the Bcl10 gene in a series of 439 tumor tissues from various histological origins that are known to have frequent loss of heterozygosity at chromosome 1p22. According to the LOH study at intragenic polymorphic sites, deletion of Bcl10 in informative cases was detected in 50% of malignant mesotheliomas, 33% of gastric carcinomas, 23% of breast carcinomas, 20% of hepatocellular carcinomas, 17% of lymphomas, 15% of colorectal carcinomas, 13% of laryngeal carcinomas, and 10% of male germ cell tumors (GCTs). In contrast, we detected Bcl10 mutations in 4 of 120 lymphomas (3.3%) and 2 of 78 GCTs (2.6%), respectively, but no mutation was found in the remaining solid tumors analyzed. Taken together, these data imply that Bcl10 may occasionally be involved in the pathogenesis of lymphoma and GCTs. However, the absence or low frequency of the mutation suggests that either Bcl10 is inactivated by other mechanisms or it is not the only target of chromosome 1p22 deletion in human tumors.

This article has been cited by other articles:

				C. Lobry, T. Lopez, A. Israel, and R. Weil Negative feedback loop in T cell activation through I{kappa}B kinase-induced phosphorylation and degradation of Bcl10 PNAS, January 16, 2007; 104(3): 908 - 913. [Abstract] [Full Text] [PDF]

				B. Maes, A. Demunter, B. Peeters, and C. De Wolf-Peeters BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression Blood, February 15, 2002; 99(4): 1398 - 1404. [Abstract] [Full Text] [PDF]

				J. C. Reed Mechanisms of Apoptosis Am. J. Pathol., November 1, 2000; 157(5): 1415 - 1430. [Abstract] [Full Text] [PDF]

				H. Ye, A. Dogan, L. Karran, T. G. Willis, L. Chen, I. Wlodarska, M. J. S. Dyer, P. G. Isaacson, and M.-Q. Du BCL10 Expression in Normal and Neoplastic Lymphoid Tissue : Nuclear Localization in MALT Lymphoma Am. J. Pathol., October 1, 2000; 157(4): 1147 - 1154. [Abstract] [Full Text] [PDF]

				E. Macintyre, D. Willerford, and S. W. Morris Non-Hodgkin's Lymphoma: Molecular Features of B Cell Lymphoma Hematology, January 1, 2000; 2000(1): 180 - 204. [Abstract] [Full Text] [PDF]